- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Lupin ropes in Jeffrey Kindler, Alfonso Zulueta as Independent Directors
Mumbai: Pharma major Lupin Limited has announced the appointment of Jeffrey Kindler and Alfonso "Chito" Zulueta as Independent Directors to its Board.
Kindler is an experienced healthcare executive, investor and advisor. He brings over four decades of business experience and has held leadership positions at some of the world’s most recognized companies including Pfizer, where he served as Chairman & Chief Executive Officer, as well as McDonald's Corporation and General Electric Company. Before that, he was a partner at law firm Williams & Connolly.
Kindler is currently CEO of Centrexion Therapeutics, a privately held biotechnology company, Senior Advisor to Blackstone, Operating Partner at ARTIS Ventures and Global Chair of GLG Institute. In addition, Kindler is member of the board of directors of a number of companies, including Precigen Inc., Perrigo Pharmaceuticals and Terns Pharmaceuticals. Kindler holds a Bachelor of Arts degree (Summa cum Laude) from Tufts University, USA and a Juris Doctor degree (Magna cum Laude) from Harvard Law School, USA.
Zulueta spent over three decades in various roles of increasing responsibility with Eli Lilly and Company, including as Vice President of Global Marketing, President of Global Oncology and Critical Care Products and most recently, as President of International responsible for all geographies outside the United States and Canada. He also served as a corporate officer and member of Eli Lilly and Company’s Executive Committee. Zulueta previously served as member of the board of the European Federation of Pharmaceutical Industries and Associations and the U.S.-Japan Business Council.
Zulueta currently serves as Non-Executive Chairman of the board of directors of Interpharma Investments Limited, the holding company of Zuellig Pharma, one of the largest healthcare services groups in Asia. He is also president/CEO of CZ Ventures, a company focused on start-up investments, and member of the board of directors at Glooko, CTS Corporation, and Bridge PayDay Solutions.
Zulueta holds an Economics undergraduate degree from De La Salle University, Manila, where he was conferred the 2023 Outstanding Alumnus Award, and MBA degree in Marketing/Finance from the University of Virginia, Darden School of Business, USA.
Commenting on the appointments, Vinita Gupta, Chief Executive Officer, Lupin said, "We are delighted to welcome Jeff and Chito to our board. Their extensive experience in building healthcare institutions, strategic perspectives of our industry and deep understanding of the evolving global pharmaceutical landscape, will enable us to advance our growth plans in the years to come."
Read also: Lupin bags USFDA nod for Travoprost Ophthalmic Solution
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751